A Hantavirus Update Has Sent This Nano-Cap Biotech Stock Surging Today – Here’s Why Retail Sees Potential 20x Gains

• Traws Pharma already develops antiviral drugs for influenza, H5N1 bird flu, and COVID-19.
• Hantavirus is a severe rodent-borne disease with a fatality rate of 30% to 50% in humans.
• The World Health Organization said the outbreak is not expected to become a pandemic like COVID-19 because the virus spreads mainly through close personal contact.

Shares of Traws Pharma (TRAW) jumped 30% in early trade on Friday after the biotech firm announced plans to advance potential clinical candidates for the treatment of hantavirus infections, as it looks to take on bigger vaccine makers like Moderna and Inovio.

The latest intraday jump extends a strong run for TRAW shares, which had already climbed about 19% in May through Thursday’s close.

What Is Hantavirus?

Hantavirus is a severe rodent-borne disease with a fatality rate of 30% to 50% in humans. The latest fear comes amid an outbreak aboard the Dutch-flagged cruise ship Hondius, which has been linked to three deaths and several infections.

The World Health Organization (WHO) said the outbreak is not expected to become a pandemic like COVID-19 because the virus spreads mainly through close personal contact. However, the agency warned that more cases could still emerge due to the disease’s incubation period, which can last up to six weeks.

TRAW Banks On Antiviral Experience

Traws Pharma said its experience in developing antiviral drugs for illnesses such as influenza, H5N1 bird flu, and COVID-19 could help support the development of new treatments for hantavirus, which currently has no approved therapy for pulmonary disease.

“Traws intends to move rapidly, using its established network of drug development and virus testing assets, to identify the optimal candidates for Hantaan virus treatment and, additionally, to access proprietary chemical libraries for homing in on the best potential treatments,” said C. David Pauza, chief scientific officer at Traws Pharma.

Retail Chatter Is Mixed On TRAW

Retail sentiment for TRAW on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes on the platform jumped 820% over the past 24 hours.

One user said the stock could see a 20x increase in value if a major outbreak occurs.

The stock has surged 90% so far in 2026.

Read also: ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy

For updates and corrections, email newsroom[at]stocktwits[dot]com.